Causes of and prevention strategies for hepatocellular carcinoma

Seminars in Oncology

Volumn 39, Issue 4, 2012, Pages 374-383

  Cabibbo, Giuseppe ^a   Maida, Marcello ^a   Genco, Chiara ^a   Antonucci, Michela ^a   Cammà, Calogero ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADEFOVIR; AFLATOXIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B VACCINE; INSULIN SENSITIZING AGENT; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLUS FLAVUS; ASPERGILLUS PARASITICUS; BEHAVIOR THERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CD8+ T LYMPHOCYTE; CHEMOPROPHYLAXIS; CONFERENCE PAPER; DIABETES MELLITUS; FOOD CONTAMINATION; HEPATITIS B; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW DRUG DOSE; MIXED INFECTION; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; STELLATE CELL; VIRUS TRANSCRIPTION;

CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; CONTROLLED CLINICAL TRIALS AS TOPIC; COUNSELING; HEPATITIS B; HEPATITIS C; HUMANS; INTERFERONS; LIVER NEOPLASMS; VACCINATION;

EID: 84864491267     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.05.006     Document Type: Conference Paper

References (128)

1. D.M. Parkin, F. Bray, J. Ferlay, P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. D.M. Parkin, F. Bray, J. Ferlay, P. Pisani Estimating the world cancer burden: Globocan 2000 Int J Cancer 94 2001 153 156
3. K.A. McGlynn, L. Tsao, A.W. Hsing, S.S. Devesa, J.F. Fraumeni Jr International trends and patterns of primary liver cancer Int J Cancer 94 2001 290 296
4. S.D. Taylor-Robinson, G.R. Foster, S. Arora, S. Hargreaves, H.C. Thomas Increase in primary liver cancer in the UK, 1979-94 Lancet 350 1997 1142 1143
5. H.B. El-Serag, A.C. Mason Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 1999 745 750
6. S.F. ltekruse, K.A. McGlynn, M.E. Reichman Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J Clin Oncol 27 2009 1485 1491
7. G. Fattovich, T. Stroffolini, I. Zagni, F. Donato Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 suppl 1 2004 S35 S50
8. G. Cabibbo, M. Enea, M. Attanasio, J. Bruix, A. Craxì, C. Cammà A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma Hepatology 51 2010 1274 1283
9. H.O. Adami, N.E. Day, D. Trichopoulos, W.C. Willett Primary and secondary prevention in the reduction of cancer morbidity and mortality Eur J Cancer 37 Suppl 8 2001 S118 S127
10. G. Cabibbo, A. Craxì Epidemiology, risk factors and surveillance of hepatocellular carcinoma Eur Rev Med Pharmacol Sci 14 2010 352 355
11. S.M. Lippman, W.K. Hong Cancer prevention by delay. Commentary re: J.A. O'Shaughnessy et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development Clin Cancer Res 8 2002 305 313
12. T. Stroffolini, E. Sagnelli, P. Almasio Italian Hospitals Collaborating Groups Characteristics of liver cirrhosis in Italy: results from a multicenter national study Dig Liver Dis 36 2004 56 60
13. H. Tsukuma, T. Hiyama, S. Tanaka Risk factors for hepatocellular carcinoma among patients with chronic liver disease N Engl J Med 24 1993 1797 1801
14. H.B. El-Serag, A.C. Mason Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 1999 745 750
15. F. Donato, P. Boffetta, M. Puoti A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma Int J Cancer 75 1998 347 354
16. M. Manno, C. Camma, F. Schepis Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years Gastroenterology 127 2004 756 763
17. M. Torbenson, D.L. Thomas Occult hepatitis B Lancet Infect Dis 2 2002 479 486
18. I. Cacciola, T. Pollicino, G. Squadrito Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease N Engl J Med 341 1999 22 26
19. T. Pollicino, G. Squadrito, G. Cerenzia Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection Gastroenterology 126 2004 102 110
20. R.G. Simonetti, C. Camma, F. Fiorello Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis A case-control study Ann Intern Med 116 1992 97 102
21. M.M. Hassan, L.Y. Hwang, C.J. Hatten Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus Hepatology 36 2002 1206 1213
22. E. Bugianesi Non-alcoholic steatohepatitis and cancer Clin Liver Dis 11 2007 191 207
23. S. Petta, A. Craxì Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association Curr Pharm Des 16 2010 741 752
24. G. Bedogni, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, S. Bellentani Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study Hepatology 42 2005 44 52
25. J.D. Browning, L.S. Szczepaniak, R. Dobbins Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 2004 1387 1395
26. G.M. Reaven The metabolic syndrome: requiescat in pace Clin Chem 51 2005 931 938
27. G. Marchesini, E. Bugianesi, G. Forlani Nonalcoholic fatty liver, steatohepatitis, and the metabolic sindrome Hepatology 37 2003 917 923
28. H.P. Cotrim, R. Parana, E. Braga, L. Lyra Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol 95 2000 3018 3019
29. Y. Zen, K. Katayanagi, K. Tsuneyama, K. Harada, I. Araki, Y. Nakanuma Hepatocellular carcinoma arising in non-alcoholic steatohepatitis Pathol Int 51 2001 127 131
30. H. Orikasa, R. Ohyama, N. Tsuda, B.P. Eyden, K. Yamazaki Lipidrich clear cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus J Submicrosc Cytol Pathol 35 2001 195 200
31. M. Shimada, E. Hashimoto, M. Taniai Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis J Hepatol 37 2002 154 160
32. S. Mori, T. Yamasaki, I. Sakaida Hepatocellular carcinoma with nonalcoholic steatohepatitis J Gastroenterol 39 2004 391 396
33. R.E. Bullock, A.M. Zaitoun, G.P. Aithal, S.D. Ryder, I.J. Beckingham, D.N. Lobo Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma J Hepatol 41 2004 685 690
34. Y. Yoshioka, E. Hashimoto, S. Yatsuji Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma and burn-out NASH J Gastroenterol 39 2004 1215 1218
35. K. Sato, Y. Ueda, K. Ueno, K. Okamoto, H. Iizuka, S. Katsuda Hepatocellular carcinoma and nonalcoholic steatohepatitis developing during long-term administration of valproic acid Virchows Arch 447 2005 996 999
36. H. Ikeda, M. Suzuki, H. Takahashi Hepatocellular carcinoma with silent and cirrhotic nonalcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder Pathol Int 56 2006 40 45
37. A.G. Renehan, M. Tyson, M. Egger, R.F. Heller, M. Zwahlen Body mass index and incidence of cancer: a systematic review and metaanalysis of prospective observational studies Lancet 371 2008 569 578
38. E.E. Calle, C. Rodriguez, K. Walker-Thurmond, M.J. Thun Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 348 2003 1625 1638
39. C. Samanic, W.H. Chow, G. Gridley, B. Jarvholm, J.F. Fraumeni Jr Relation of body mass index to cancer risk in 362,552 Swedish men Cancer Causes Control 17 2006 901 909
40. A. Wolk, G. Gridley, M. Svensson A prospective study of obesity and cancer risk (Sweden) Cancer Causes Control 12 2001 13 21
41. C. Samanic, G. Gridley, W.H. Chow, J. Lubin, R.N. Hoover, J.F. Fraumeni Jr Obesity and cancer risk among white and black United States veterans Cancer Causes Control 15 2004 35 43
42. H. Moller, A. Mellemgaard, K. Lindvig, J.H. Olsen Obesity and cancer risk: a Danish record-linkage study Eur J Cancer 30A 1994 344 350
43. S.W. Oh, Y.S. Yoon, S.A. Shin Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study J Clin Oncol 23 2005 4742 4754
44. S.C. Larsson, A. Wolk Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies Br J Cancer 97 2007 1005 1008
45. J.A. Davila, R.O. Morgan, Y. Shaib, K.A. McGlynn, H.B. El-Serag Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study Gut 54 2005 533 539
46. H.B. El-Serag, P.A. Richardson, J.E. Everhart The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans Am J Gastroenterol 96 2001 2462 2467
47. M.C. Yu, M.J. Tong, S. Govindarajan, B.E. Henderson Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California J Natl Cancer Inst 83 1991 1820 1826
48. M.M. Hassan, L.Y. Hwang, C.J. Hatten Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus Hepatology 36 2002 1206 1213
49. J.M. Yuan, S. Govindarajan, K. Arakawa, M.C. Yu Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S Cancer 101 2004 1009 1017
50. C. La Vecchia, E. Negri, A. Decarli, S. Franceschi Diabetes mellitus and colorectal cancer risk Cancer Epidemiol Biomarkers Prev 6 1997 1007 1010
51. P. Lagiou, H. Kuper, S.O. Stuver, A. Tzonou, D. Trichopoulos, H.O. Adami Role of diabetes mellitus in the etiology of hepatocellular carcinoma J Natl Cancer Inst 92 2000 1096 1099
52. J.H. Kao, D.S. Chen Global control of hepatitis B virus infection Lancet Infect Dis 2 2002 395 403
53. R.E. Omer, A. Kuijsten, A.M. Kadaru Population-attributable risk of dietary aflatoxins and hepatitis B virus infection with respect to hepatocellular carcinoma Nutr Cancer 48 2004 15 21
54. P. Almasio, C. Camma, M. Giunta Treatment of chronic hepatitis B: an evidence-based review J.W.D. McDonald, A. Burroughs, B.G. Feagan, Evidence-based gastroenterology and hepatology 1999 BMJ Publications London 305 321
55. C.J. Oon Long term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Welferon in the prophylaxis of high risk pre-cancerous conditions Cancer Chemoter Pharmacol 31 Suppl 1 1992 S137 S142
56. G. Mazzella, E. Accogli, S. Sottili Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related cirrhosis J Hepatol 24 1996 141 147
57. G. Fattovich, G. Giustina, G. Realdi European Concerted Action on Viral Hepatitis (EUROHEP) Long term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alpha Hepatology 26 1997 1338 1342
58. L. Benvegnù, L. Chemello, F. Noventa Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis Cancer 83 1998 901 909
59. K. Ikeda, S. Saitoh, Y. Suzuki Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus Cancer 82 1998 827 835
60. International Interpheron-alpha Hepatocellular Carcinoma Study Group Effect of interpheron alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study Lancet 351 1998 1535 1539
61. V. Di Marco, O. Lo Iacono, C. Cammà The long term course of chronic hepatitis B Hepatology 30 1999 257 264
62. S.M. Lin, I.S. Sheen, R.N. Chien Long term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection Hepatology 29 1999 971 975
63. G.V. Papatheodoridis, E. Manesis, S.J. Hadziyannis The long term outcome of interferon alpha treated and untreated patients with HBeAg-negative chronic hepatitis B J Hepatol 34 2001 306 313
64. P. Tankijvanich, D. Thomg-ngam, V. Mahachai, N. Kladchareon, P. Suwangool, P. Kullavanijaya Long term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B Southeast Asian J Trop Med Public Health 32 2001 452 458
65. M.F. Yuen, C.K. Hui, C.C. Cheng Long term follow up of interferon alpha treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications Hepatology 34 2001 139 145
66. A. Craxì, C. Cammà Prevention of hepatocellular carcinoma Clin Liver Dis 9 2005 329 346
67. C. Niederau, T. Heinges, S. Lange Long term follow up of HBeAg positive patients treated with interferon alfa for chronic Hepatitis B N Engl J Med 334 1996 1422 1427
68. D.K. Che, C. Yim, K. O'Rourke Long term follow up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population J Hepatol 30 1999 557 563
69. A.A. Evans, M. Fine, W.T. London Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy J Infect Dis 176 1997 845 850
70. J. Korenman, B. Baker, J. Waggoner Long term remission of chronic hepatitis B after alpha interferon therapy Ann Intern Med 114 1991 629 634
71. A.S. Lok, H.T. Chung, V.W. Liu Long term follow up of chronic hepatitis B patients treated with interferon alpha Gastroenterology 105 1993 1833 1838
72. D.T. Lau, J. Everhart, D.E. Kleiner Long term follow up of patients with chronic hepatitis B treated with interferon alpha Gastroenterology 113 1997 1660 1667
73. G. Fattovich, G. Giustina, E. Christensen Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B: the European Concerted Action on Viral Hepatitis (Eurohep) Gut 46 2000 420 426
74. Y.S. hsu, R.N. Chien, C.T. Yeh Long term outcome after spontaneous HBeAgseroconversion in patients with chronic hepatitis B Hepatology 35 2002 1522 1527
75. P. Lampertico, E. Del Ninno, M. Viganò Long term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24v moth interferon therapy Hepatology 37 2003 756 763
76. J.J. Sung, K.K. Tsoi, V.W. Wong Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma Aliment Pharmacol Ther 28 2008 1067 1077
77. Y.F. Yang, W. Zhao, Y.D. Zhong Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis J Viral Hepatol 16 2009 265 271
78. C. Chien-Jen, Y. Hwai-I, S. Jun REVEAL-HBV Study Group Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
79. Y.F. Liaw, J.J.Y. Sung, W.C. Chow Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
80. A. Matsumoto, E. Tanaka, A. Rokuhara Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multi center retrospective study of 3975 patients Hepatol Res 32 2005 172 184
81. G.V. Patheodoridis, E. Dimou, K. Dimakopoulos Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analogue therapy starting with lamivudine Hepatology 42 2005 121 129
82. M.F. Yuen, W.K. Seto, D.H. Chow Long term lamivudine therapy reduces the risk of long term complications of chronic hepatitis B infection even in patients without advanced disease Antiviral Ther 12 2007 1295 1303
83. J.R. Eun, H.J. Lee, S.H. Lee The effect of lamivudine and adefovirdipivoxil on preventing hepatocellular carcinoma in hepatitis B virus related liver cirrhosis Hepatology 46 Suppl 1 2007 664A 665A
84. P. Lampertico, M. Viganò, E. Manenti, M. Iavarone, E. Sablon, M. Colombo Low resistance to adefovir combined with lamivudine: a 3 year study of 145 lamivudine resistant hepatitis B patients Gastroenterology 133 2007 1718 1721
85. S. Nishiguchi, T. Kuroki, S. Nakatani Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1995 1051 1055
86. L. Benvegnu, L. Chemello, F. Noventa Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis Cancer 83 1998 901 909
87. International Interferon-alpha Hepatocellular Carcinoma Study Group Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study Lancet 351 1998 1535 1539
88. G. Mazzella, E. Accogli, S. Sottili Alpha-interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis J Hepatol 24 1996 141 147
89. S. Bruno, E. Silini, A. Crosignani Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study Hepatology 25 1997 754 758
90. G. Fattovich, G. Giustina, F. Degos Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
91. Y. Imai, S. Kawata, S. Tamura Osaka Hepatocellular Carcinoma Prevention Study Group Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C Ann Intern Med 129 1998 94 99
92. A. Gramenzi, P. Andreone, S. Fiorino Impact of interferon therapy on the natural history of HCV-related cirrhosis Gut 48 2001 843 848
93. L. Serfaty, H. Aumaître, O. Cazouillères Determinants of outcome of compensated hepatitis C virus-related cirrhosis Hepatology 27 1998 1435 1440
94. S. Sofia, A. Casali, E. Buscarini Effect of lymphoblastoid IFN in the treatment of liver cirrhosis and prevention of HCC Ital J Gastroenterol Hepatol 30 1998 A31
95. A. Shioda, M. Moriyama, M. Kaneko Long-term prognosis of hepatocellular carcinoma developing after treatment of interferon in patients with chronic hepatitis C and liver cirrhosis Hepatology 30 1999 268A
96. H. Yoshida, Y. Shiratori, M. Moriyama IHIT Study Group Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non cirrhotic patients with chronic hepatitis C in Japan Ann Intern Med 131 1999 174 181
97. D. Mura, R. Deliperi, L. Fastame Five year follow-up after Interferon therapy in HCV-positive compensated cirrhosis Ital J Gastroenterol Hepatol 30 1998 A114
98. D.-C. Valla, M. Chevallier, P. Marcellin Treatment of hepatitis C virus-related cirrhosis: a randomized controlled trial of interferon alfa 2b versus no treatment Hepatology 583 1999 29 1870-5
99. T. Okanoue, Y. Itoh, M. Minami Viral Hepatitis Therapy Study Group Interferon therapy lower sthe rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients J Hepatol 30 1999 653 659
100. H. Toyoda, T. Kumada, S. Nakano The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C Cancer 88 2000 58 65
101. K. Ikeda, M. Kobayashi, S. Saitoh Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy A closed cohort study including matched control patients Oncology 65 2003 204 210
102. G. Testino, F. Ansaldi, E. Andorno Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis Hepatogastroenterology 49 2002 1636 1638
103. R. Planas, J.C. Quer, J. Enríquez Induction therapy with interferon alfa-2a in compensated hepatitis C virus-related cirrhosis Randomized, multicenter study Med Clin (Barc) 118 2002 641 644
104. H. Yoshida, R. Tateishi, Y. Arakawa Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C Gut 53 2004 425 430
105. C. Cammà, M. Giunta, P. Andreone Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach J Hepatol 34 2001 593 602
106. G.V. Papatheodoridis, V.C. Papadimitropoulos, S.J. Hadziyannis Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis Aliment Pharmacol Ther 15 2001 689 698
107. Y. Shiratori, Y. Ito, O. Yokosuka Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival Ann Intern Med 142 2005 105 114
108. M.L. Yu, S.M. Lin, C.M. Lee A simple non invasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy Hepatology 44 2006 1086 1097
109. S. Bruno, T. Stroffolini, M. Colombo Sustained virologic response to interferon-a is associated with improved outcome in HCV-related cirrhosis: a retrospective study Hepatology 45 2007 579 587
110. A.M. Di Bisceglie, M.L. Shiffman, G.T. Everson Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
111. T. Poynard, M. Colombo, J. Bruix Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 2009 1618 1628
112. N. Afdhal, R. Levine, R. Brown Jr Colchicine versus PEG interferon alfa 2B long term therapy: results of the 4 year copilot trial J Hepatol 48 2008 S4
113. S. Bellentani, R. Dalle Grave, A. Suppini, G. Marchesini Fatty Liver Italian Network. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach Hepatology 47 2008 746 754
114. R. Belfort, S.A. Harrison, K. Brown A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 355 2006 2297 2307
115. G.P. Aithal, J.A. Thomas, P.V. Kaye Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis Gastroenterology 135 2008 1176 1184
116. V. Ratziu, P. Giral, S. Jacqueminet LIDO Study Group Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial Gastroenterology 135 2008 100 110
117. E. Bugianesi, E. Gentilcore, R. Manini A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease Am J Gastroenterol 100 2005 1082 1090
118. D.M. Torres, S.A. Harrison Diagnosis and therapy of nonalcoholic steatohepatitis Gastroenterology 134 2008 1682 1698
119. J. Yu, L. Qiao, L. Zimmermann Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo Hepatology 43 2006 134 143
120. M.C. Hsu, C.C. Huang, H.C. Chang, T.H. Hu, W.C. Hung Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor γ ligands in vitro and in vivo Clin Cancer Res 14 2008 4045 4052
121. E. Bråkenhielm, N. Veitonmäki, R. Cao Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis Proc Natl Acad Sci U S A 101 2004 2476 2481
122. M. Awazawa, K. Ueki, K. Inabe Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway Biochem Biophys Res Commun 382 2009 51 56
123. K.R. Kim, H.N. Choi, H.J. Lee A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma Oncol Rep 18 2007 825 832
124. K.L. Schaefer, K. Wada, H. Takahashi Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells Cancer Res 65 2005 2251 2259
125. J.M. Evans, L.A. Donnelly, A.M. Emslie-Smith, D.R. Alessi, A.D. Morris Metformin and reduced risk of cancer in diabetic patients BMJ 330 2005 1304 1305
126. Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer? Diabetologia. DOI 10.1007/s00125-009-1441-5.
127. M. Buzzai, R.G. Jones, R.K. Amaravadi Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth Cancer Res 67 2007 6745 6752
128. I. Ben Sahra, K. Laurent, A. Loubat The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level Oncogene 27 2008 3576 3586